Status:
COMPLETED
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
Lead Sponsor:
Ligand Pharmaceuticals
Conditions:
Osteoporosis
Eligibility:
FEMALE
40-80 years
Phase:
PHASE2
Brief Summary
To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.
Eligibility Criteria
Inclusion
- postmenopausal Asian women with osteoporosis defined by low BMD
Exclusion
- Metabolic bone disease, use of other osteoporosis drugs or drugs interering with normal bone metabolism
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
497 Patients enrolled
Trial Details
Trial ID
NCT00143273
Start Date
June 1 2004
End Date
March 1 2006
Last Update
August 10 2011
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan, 810-0021
2
Pfizer Investigational Site
Kagoshima, Kagoshima-ken, Japan, 892-0824
3
Pfizer Investigational Site
Kagoshima, Kagoshima-ken, Japan, 892-0845
4
Pfizer Investigational Site
Miyazaki, Miyazaki, Japan, 880-0052